The short version of incretin fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-10-24 and is reviewed periodically as new material appears.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Body composition is assessed with dual-energy X-ray absorptiometry or comparable methods, which separate fat mass from lean mass. Reported losses include both compartments, and the ratio between them is a subject of ongoing analysis rather than a settled result. Waist circumference, blood pressure, and lipid panels are collected as supporting measures. Resting energy expenditure and substrate oxidation are measured in smaller mechanistic studies, where glucagon receptor activity is expected to matter. These substudies are typically short and small, so their findings carry wide uncertainty.
Interpretation depends on study phase and duration. Phase 2 programs are powered for weight and safety signals, not for cardiovascular or renal outcomes, which require event-driven designs. Gastrointestinal events such as nausea, diarrhea, vomiting, and constipation are the most frequently reported adverse effects and tend to cluster around dose escalation. Small increases in heart rate have been described. Because follow-up after treatment discontinuation is limited, questions about weight regain and durability are open rather than answered.
| Property | Value | Notes |
|---|---|---|
| Receptor targets | GIP, GLP-1, glucagon | One molecule activates all three pathways |
| Research identifier | LY3437943 | Code used in published trial reports |
| Development stage | Phase 3, reported as ongoing | Not approved by any regulatory agency |
| Route studied | Subcutaneous | Administration form used in clinical trials |
| Studied populations | Adults with obesity or type 2 diabetes | Enrollment criteria vary between trials |
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
As a peptide, the compound is generally supplied as a lyophilized powder and stored frozen to slow degradation. Recommended conditions usually sit at minus twenty degrees Celsius or colder, shielded from light and moisture. Solutions are less stable than the dry powder and are often prepared fresh before analysis. Repeated freeze-thaw cycles can drive aggregation, so splitting stock material into small aliquots reduces handling stress and preserves sample integrity.
Quality control of research material relies on several complementary checks. Purity testing confirms the absence of truncated or oxidized peptide species, while water content and counterion analysis show how much mass comes from salts rather than the peptide itself. Sequence verification through tandem mass spectrometry ensures the correct amino acid chain. Because unregulated suppliers vary widely, independent verification of identity and purity is often necessary before a sample enters experiments.
In later years, the arsons continued, but the frequency of these fires was reduced by razing thousands of abandoned houses and buildings that were often used to sell drugs. Five thousand of these buildings were razed in 1989–90 alone. The city mobilizes "Angel's Night" every year, with tens of thousands of volunteers patrolling high-risk areas.
Removal of the acetyl group yields ornithine, which enters the urea cycle. Deacetylation can occur either through simple hydrolysis (via acetylornithinase) or by transfer of the acetyl group to glutamic acid with regeneration of N-acetylglutamate. Acetylation presumably serves to separate the biosynthetic pathways of arginine and proline, as the non-acetylated glutamate-5-semialdehyde readily cyclizes to pyrroline-5-carboxylic acid. The biosynthetic pathway to ornithine as a precursor of arginine via N-acetylglutamate with recovery of the acetyl group occurs not only in many bacteria but also in plants and fungis, but not in animals. Arginine is subsequently formed from ornithine via the urea cycle.
== Awards and honors == United States National Academy of Sciences, member – 1942 Willard Gibbs Medal – 1943 American Philosophical Society, member – 1947 Albert Lasker Award for clinical medical research – 1952 American Academy of Arts and Sciences, member – 1953
=== Enzymes === Peripheral enzymes participate in metabolism of different membrane components, such as lipids (phospholipases and cholesterol oxidases), cell wall oligosaccharides (glycosyltransferase and transglycosidases), or proteins (signal peptidase and palmitoyl protein thioesterases). Lipases can also digest lipids that form micelles or nonpolar droplets in water.
Sources: en.wikipedia.org
== Bibliography == J. Samuel Walker (November 1, 2000). Permissible Dose: A History of Radiation Protection in the Twentieth Century. University of California Press. ISBN 978-0-520-92484-0. Limited preview in Google Books. K. N. Govinda Rajan (July 28, 2017). Radiation Safety in Radiation Oncology. CRC Press. ISBN 978-1-4987-6226-7. Limited preview in Google Books. Strahlengefahrdung und Strahlenschutz / Radiation Exposure and Radiation Protection. Springer-Publisher. March 13, 2013. ISBN 978-3-642-82229-2. Limited preview in Google Books J. Samuel Walker (April 2001). Short History of Nuclear Regulation, 1946–1999. DIANE Publishing. ISBN 978-0-7567-0929-7.Limited preview in Google Books. Ashley W. Oughterson, Shields Warren: Medical Effects of the Atomic Bomb in Japan. Volume VIII.8 aus der National Nuclear Energy Series zum Manhattan Project, McGraw-Hill Book Company, 1956. Carl Voegtlin, Harold C. Hodge: Pharmacology and Toxicology of Uranium Compounds. Volume VI.1, Part I and Part II (with a Section on the Pharmacology and Toxicology of Fluorine and Hydrogen Fluoride) from the National Nuclear Energy Series to the Manhattan Project, McGraw-Hill Book Company, 1949. Henry DeWolf Smyth (written on the request of Maj. Gen. L. R. Groves): Atomic Energy for Military Purposes. The official report on the development of the atomic bomb under the auspices of the United States Government, 1940–1945. Princeton University Press, 1946. James E. Grindler (Argonne National Laboratory): The Radiochemistry of Uranium.
=== Morphology === "Candidatus Magnetoglobus multicellularis" is an obligately multicellular bacteria without a unicellular stage in its lifecycle. It typically consists of 10–40 bacterial cells in an organised spherical structure surrounding an acellular compartment. The entire organism has a diameter of approximately 3 to 12 micrometres. Individual cells are elongated into a pyramidal shape, with the narrow apex facing the acellular compartment in the centre. The outward-facing surface of each cell houses numerous flagella. The cells are all tightly joined by highly specialised intercellular junctions, similar to those found in eukaryotic multicellular organisms. The exterior of the organism features a cellulose matrix that plays a role in cell adhesion and structural integrity.
Omeprazole, sold under the brand names Prilosec and Losec among others, is a medication used in the treatment of gastroesophageal reflux disease (GERD), peptic ulcer disease, and Zollinger–Ellison syndrome. It is also used to prevent upper gastrointestinal bleeding in people who are at high risk. Omeprazole is a proton-pump inhibitor (PPI) and its effectiveness is similar to that of other PPIs. It can be taken by mouth or by injection into a vein. It is also available in the fixed-dose combination medication omeprazole/sodium bicarbonate as Zegerid and as Konvomep. Common side effects include nausea, vomiting, headaches, abdominal pain, and increased intestinal gas. Serious side effects may include Clostridioides difficile colitis, an increased risk of pneumonia, an increased risk of bone fractures, and the potential of masking stomach cancer. Whether it is safe for use in pregnancy is unclear. It works by blocking the release of stomach acid. Omeprazole was patented in 1978 and approved for medical use in 1988. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication. In 2023, it was the tenth most commonly prescribed medication in the United States, with more than 45 million prescriptions. It is also available without a prescription in the United States.
== Sources and composition == Silk is not a single substance but a family of fibrous proteins spun by several different animals, and the silks used as biomaterials differ both in their origin and in the proteins they contain.
=== Ireland === In 2019, the chain announced plans to open a restaurant in Dublin, Ireland, with 40 total sites in Ireland planned from 2020. As of early 2026, there are two locations in Ireland, both of them in Dublin.
Sources: en.wikipedia.org
=== Endovascular cytotrophoblast === The primary function of the endovascular cytotrophoblast is to penetrate maternal spiral arteries and route the blood flow through the placenta for the growing embryo to use. They arise from interstitial cytotrophoblasts from the process of phenocopying. This changes the phenotype of these cells from epithelial to endothelial. Endovascular cytotrophoblasts, like their interstitial predecessor, are non-proliferating and invasive.
A helix has an overall dipole moment due to the aggregate effect of the individual microdipoles from the carbonyl groups of the peptide bond pointing along the helix axis. The effects of this macrodipole are a matter of some controversy. α-helices often occur with the N-terminal end bound by a negatively charged group, sometimes an amino acid side chain such as glutamate or aspartate, or sometimes a phosphate ion. Some regard the helix macrodipole as interacting electrostatically with such groups. Others feel that this is misleading and it is more realistic to say that the hydrogen bond potential of the free NH groups at the N-terminus of an α-helix can be satisfied by hydrogen bonding; this can also be regarded as set of interactions between local microdipoles such as C=O···H−N.
Counter-Strike: Source is a tactical first-person shooter video game developed by Valve and Turtle Rock Studios. Released in October 2004 for Windows, it is a remake of Counter-Strike (2000) using the Source game engine. As in the original, Counter-Strike: Source pits a team of counter-terrorists against a team of terrorists in a series of rounds. Each round is won either by completing an objective (such as detonating a bomb or rescuing hostages) or by eliminating all members of the enemy team. The game was initially bundled with all retail and digital copies of Half-Life 2, before being released standalone.
Tin-121m (121mSn) is a nuclear isomer of tin with a half-life of 43.9 years, making it technically a medium-lived fission product. In a normal thermal reactor, it has a very low fission product yield; thus, this isotope is not a significant contributor to nuclear waste. Fast fission or fission of some heavier actinides will produce it at higher yields. For example, its yield from uranium-235 is 0.0007% per thermal fission and 0.002% per fast fission.
Sources: en.wikipedia.org
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.
No regulatory agency has approved it for any indication. It remains an investigational product studied within controlled clinical trial programs.
A dual agonist engages two receptor targets, typically GIP and GLP-1. A triagonist adds glucagon receptor activity, which is intended to influence energy expenditure alongside appetite and glucose handling.
A responder analysis counts participants who cross a threshold, such as five or ten percent weight loss. It complements average percent change by showing how widely results are distributed. The two measures can diverge when a subset of participants loses a large amount.